Allogeneic Transplant
Busulfan/cycloPHOSphamide–MAC–MUD
Indication
00639a
Myeloablative conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders
Busulfan/cycloPHOSphamide – MAC – SIB
Indication
00641a
Myeloablative conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.
Busulfan/cycloPHOSphamide/ATG Grafalon® – MAC – Mismatched Sibling Donor
Indication
00662a
Myeloablative conditioning for mismatched sibling donor allogeneic stem cell transplant in patients with myeloid disorders.
Busulfan/cycloPHOSphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor
Indication
00663a
Myeloablative conditioning for mismatched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders
Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD
Indication
00638a
Reduced intensity conditioning for sibling or matched unrelated allogeneic stem cell transplantation in Hodgkins and Non-Hodgkins Lymphoma
cycloPHOSphamide/Total Body Irradiation (TBI)–MAC–MUD
Indication
00631a
Myeloablative conditioning (MAC) for matched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.
cycloPHOSphamide/Total Body Irradiation (TBI)–MAC– SIB
Indication
00637a
Myeloablative conditioning (MAC) for sibling donor allogeneic stem cell transplant in patients with lymphoid disorders
cycloPHOSphamide/Total Body Irradiation (TBI)–MAC– Mismatched Sibling Donor
Indication
00630a
Myeloablative conditioning (MAC) for mismatched sibling donor allogeneic stem cell transplant in patients with lymphoid disorders
cycloPHOSphamide/Total Body Irradiation (TBI)–MAC– Mismatched Unrelated Donor
Indication
00629a
Myeloablative conditioning (MAC) for mismatched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias
Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD
Indication
00635a
Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.
Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB
Indication
00636a
Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.
Fludarabine/ Melphalan with-post transplant cycloPHOSphamide Therapy
Indication
00868a
Reduced Intensity Conditioning with Fludarabine and Melphalan for Mismatched Unrelated Donors or physician choice for myeloid and lymphoid malignancies.
Fludarabine/Melphalan/Alemtuzumab-RIC-MUD
Indication
00625a
Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with lymphoproliferative disorders.
Fludarabine/Melphalan/Alemtuzumab-RIC-SIB
Indication
00611a
Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with lymphoproliferative disorders
Fludarabine/Melphalan/ATG Grafalon® - post-transplant Methotrexate – RIC – SIB
Indication
00922a
Reduced intensity conditioning for sibling donor allogenic stem cell transplant in patuients with myeloid disorders
Fludarabine/Busulfan (FluBu4) – with post-transplant cycloPHOSphamide Therapy (PTCy)
Indication
00910a
Myeloablative conditioning with fludarabine and busulfan for matched and mismatched donor with peripheral blood stem cells (PBSC)
Fludarabine/Busulfan (FluBu2) – with post-transplant cycloPHOSphamide Therapy (PTCy)
Indication
00911a
Reduced intensity conditioning with fludarabine and busulfan for matched and mismatched unrelated donor and peripheral blood stem cells (PBSC)
Fludarabine and Total Body Irradiation (Flu/TBI) with post-transplant cycloPHOSphamide Therapy (PTCy)
Indication
00913a
Acute lymphoblastic leukaemia (ALL), myeloablative conditioning (MAC)
with peripheral blood stem cell (PBSC) or mismatched donor
Fludarabine/Melphalan/ATG Grafalon® - post-transplant Methotrexate – RIC – MUD
Indication
00923a
Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders
Autologous Transplant
BEAM Autologous Transplant Conditioning Protocol
Indication
00408a
Autologous conditioning in non-Hodgkins Lymphoma (NHL)
00408b
Autologous conditioning in Hodgkins Lymphoma
LEAM Autologous Transplant Conditioning Protocol
Indication
00468a
Autologous conditioning in non-Hodgkins Lymphoma (NHL)
00468b
Autologous conditioning in Hodgkins Lymphoma
High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant
Indication
00454a
Conditioning Therapy in patients with Multiple Myeloma prior to autologous stem cell transplant
00454b
Conditioning Therapy in patients with other plasma cell dyscrasia such as AL amyloidosis